[Jindic: Trivalent influenza vaccine has obtained a drug registration certificate, annual revenue may be less than 100 million yuan and may be subject to delisting risk warning] On October 9th, Jindike (688670.SH) announced that the company recently received the "Drug Registration Certificate" for the influenza virus split vaccine approved by the State Food and Drug Administration. Affected by the WHO's adjustment to the recommended components of influenza vaccines, the company will no longer sell quadrivalent influenza vaccines this influenza season, and will only sell trivalent influenza vaccines. Because the product has just been approved, there are currently no products available for sale, and the time window for large-scale sales has been missed. After preliminary calculations, it is expected that the full-year revenue may be less than 100 million yuan and the company will not be able to turn around losses. If it encounters a financial delisting risk warning situation, the Shanghai Stock Exchange will implement a "delisting risk warning" on the company's stocks.